Virologic and Immunologic Characterization of Coronavirus Disease 2019 Recrudescence After Nirmatrelvir/Ritonavir Treatment

Author:

Carlin Aaron F1,Clark Alex E1,Chaillon Antoine1,Garretson Aaron F1,Bray William2,Porrachia Magali1,Santos AsherLev T3,Rana Tariq M4,Smith Davey M15

Affiliation:

1. Department of Medicine, University of California, San Diego School of Medicine , La Jolla, California , USA

2. Department of Pediatrics, University of California, San Diego School of Medicine , La Jolla, California , USA

3. Department of Public Health, College of Education, Health and Human Services, California State University San Marcos , San Marcos, California , USA

4. Division of Genetics, Department of Pediatrics, Program in Immunology, Institute for Genomic Medicine, UCSD Center for AIDS Research, University of California, San Diego , La Jolla, California , USA

5. Veterans Affairs San Diego Healthcare System , San Diego, California , USA

Abstract

Abstract We isolated a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) BA.2 variant from a person with coronavirus disease 2019 recrudescence after nirmatrelvir/ritonavir treatment. Antiviral sensitivity and neutralizing antibody testing were performed with both parental SARS-CoV-2 and multiple variants of concern. We found that neither nirmatrelvir resistance nor absence of neutralizing immunity was a likely cause of the recrudescence.

Funder

NIH

San Diego Center for AIDS Research

John and Mary Tu Foundation

James B. Pendleton Charitable Trust

Burroughs Wellcome Fund

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Microbiology (medical)

Reference4 articles.

1. EPIC-HR Investigators. Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19;Hammond;N Engl J Med,2022

2. Rapid relapse of symptomatic Omicron SARS-CoV-2 infection following early suppression with nirmatrelvir/ritonavir;Charness

3. Assignment of epidemiological lineages in an emerging pandemic using the pangolin tool;O’Toole;Virus Evol,2021

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3